Juventas (Drug Discovery) Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 22

Juventas (Drug Discovery) General Information

Description

Manufacturer of CAR-T cell therapy drugs and innovative cell biopharmaceuticals designed to treat hematologic malignancies, solid tumors, and autoimmune diseases. The company's manufacturing capabilities utilize humanized CAR-T cell engineering, viral vector construction, automated cell processing, and commercial-scale GMP cell manufacturing, providing specialized hospitals, hematology centers, and clinical researchers with NMPA-approved CD19 CAR-T cell drug products, multi-target cellular immunotherapy drugs, and clinical-stage cell therapy drug pipelines to facilitate targeted treatment for leukemia, lymphoma, and severe autoimmune conditions.

Contact Information

Website
www.juventas.cn
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 5, Number 8, Haitai Development Third Road, Huayuan Industrial Park
  • Binhai High-tech Zone
  • Tianjin, 300384
  • China
+86 022
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Building 5, Number 8, Haitai Development Third Road, Huayuan Industrial Park
  • Binhai High-tech Zone
  • Tianjin, 300384
  • China
+86 022

Juventas (Drug Discovery) Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Juventas (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 31-May-2024 Completed Generating Revenue
7. Later Stage VC (Series C2) 25-Jun-2023 Completed Generating Revenue
6. Secondary Transaction - Private 24-Oct-2022 Completed Generating Revenue
5. Later Stage VC (Series C) 12-Jul-2021 Completed Generating Revenue
4. Early Stage VC (Series B) 30-Sep-2020 Completed Generating Revenue
3. Grant 01-Jan-2020 Completed Generating Revenue
2. Early Stage VC (Series A1) 01-Jun-2019 $14.6M $38.1M Completed Generating Revenue
1. Early Stage VC (Series A) 13-Dec-2018 $23.5M $23.5M Completed Generating Revenue
To view Juventas (Drug Discovery)’s complete valuation and funding history, request access »

Juventas (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of CAR-T cell therapy drugs and innovative cell biopharmaceuticals designed to treat hematologic malignanci
Drug Discovery
Tianjin, China

Shanghai, China
 

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Juventas (Drug Discovery) Competitors (12)

One of Juventas (Drug Discovery)’s 12 competitors is JW Therapeutics, a Formerly VC-backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
JW Therapeutics Formerly VC-backed Shanghai, China
FosunKairos Venture Capital-Backed Shanghai, China
Corvus Pharmaceuticals Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 12 competitors. Get the full list »

Juventas (Drug Discovery) Patents

Juventas (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025228181-A1 Enhanced chimeric antigen receptor and use thereof Pending 30-Apr-2024
WO-2025108294-A1 Cd7-targeting humanized antibody, chimeric antigen receptor, and use thereof Inactive 21-Nov-2023
WO-2025015726-A1 Antibody against cd19 antibody, antibody against cd22 antibody, and uses thereof Inactive 20-Jul-2023
WO-2025015726-A9 Antibody against cd19 antibody, antibody against cd22 antibody, and uses thereof Inactive 20-Jul-2023
US-20230272069-A1 Chimeric antigen receptor targeting cd22 and cd19 and application thereof Pending 28-Feb-2022 C07K14/70578
To view Juventas (Drug Discovery)’s complete patent history, request access »

Juventas (Drug Discovery) Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
Baochuang Capital Growth/Expansion Minority
GDD Industry Fund Government Minority
Guangdong Technology Financial Group Government Minority
Guangzhou Industrial Investment Holding Group Government Minority
Guangzhou Science and Technology Financial Innovation Investment Holding Venture Capital Minority
You’re viewing 5 of 22 investors. Get the full list »

Juventas (Drug Discovery) FAQs

  • When was Juventas (Drug Discovery) founded?

    Juventas (Drug Discovery) was founded in 2018.

  • Where is Juventas (Drug Discovery) headquartered?

    Juventas (Drug Discovery) is headquartered in Tianjin, China.

  • What industry is Juventas (Drug Discovery) in?

    Juventas (Drug Discovery)’s primary industry is Drug Discovery.

  • Is Juventas (Drug Discovery) a private or public company?

    Juventas (Drug Discovery) is a Private company.

  • What is Juventas (Drug Discovery)’s current revenue?

    The current revenue for Juventas (Drug Discovery) is .

  • How much funding has Juventas (Drug Discovery) raised over time?

    Juventas (Drug Discovery) has raised $180M.

  • Who are Juventas (Drug Discovery)’s investors?

    Baochuang Capital, GDD Industry Fund, Guangdong Technology Financial Group, Guangzhou Industrial Investment Holding Group, and Guangzhou Science and Technology Financial Innovation Investment Holding are 5 of 22 investors who have invested in Juventas (Drug Discovery).

  • Who are Juventas (Drug Discovery)’s competitors?

    JW Therapeutics, FosunKairos, Corvus Pharmaceuticals, Kite Pharma, and Inovio Pharmaceuticals are some of the 12 competitors of Juventas (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process